Recent

% | $
Quotes you view appear here for quick access.

Inovio Pharmaceuticals, Inc. Message Board

  • kyle.ramer kyle.ramer Sep 11, 2013 5:44 PM Flag

    HIV Therapeutic results(for the data fiends)

    Between now and the end of October data will be here Pennvax's therapeutic results..I say this because PennvaxGP phase 1 trial is due to launch this month (sep 2013) as confrimed in may at the hvtn' closed mtg, PennvaxGP is a preventive and therapeutic vaccine

    Therapeutic results for Pennvax were presented in a closed mtg March 5th at the CROI conference 2013

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Ehy Kyle,
      I think the real deal here is with the HEP-B program. What's your take on that?

    • Bump

    • TY Kyle

    • Potent Cellular Immune Responses Induced after Therapeutic Immunization of HIV+ Patients with PENNVAX-B DNA Vaccine Delivered by Electroporation

      Lorenzo Ramirez*1, T Arango1, D Shah2, M Morrow2, J Lee2, M Naji1, K Maffei3, M Bagarazzi2, P Tebas3, and J Boyer1

      1Univ of Pennsylvania Perelman Sch of Med, Philadelphia, US; 2Inovio Pharmaceuticals, Blue Bell, PA, US; and 3Univ of Pennsylvania, Philadelphia, US

      Background: The goal of eradicating the HIV reservoir has renewed interest in immunotherapeutic approaches to boost T cell responses against HIV+ cells. However, individuals chronically infected with HIV respond poorly to T cell vaccines. We evaluated the use of PENNVAX-B vaccine (a gag, pol, and env combination DNA vaccine) delivered by in vivo electroporation (EP) that has proven immunogenic in HIV– individuals (HVTN 080).

      Methods: We conducted a phase 1 study in well controlled, ART treated, HIV+ individuals (HIV RNA 400/µL, and nadir CD4 cells 200 cells/µL). Subjects received 4 doses (at day 0, weeks 4, 8, and 16) of 3 mg PENNVAX-B (consisting of consensus sequence HIV gag, pol, and env immunogens) intramuscularly followed by EP. Standard IFN-? ELISpot assays were performed. Positive responses were determined using a one-way ANOVA followed by Dunnett’s test, comparing each time-point to baseline. We measured the potential of cells to lyse HIV-1+ cells by measuring CD8+CD107a+ Perforin+ Granzyme B+ responses, by standard flow cytometry. Subjects were considered responders to the vaccine if responses were 50% greater than baseline. Also, the subjects’ pre-vaccination cytokine profiles were examined using a 30 cytokine Luminex plasma assay. We compared baseline cytokine profiles of the subjects who responded via ELISpot or Flow assays to those who did not respond.

      Results: 12 subjects were included. 92% were male and 58% black. The vaccine was safe and well tolerated. 10 of the 12 subjects (83%) showed significant vaccine-specific T cell responses in the form of IFN-? ELISpot to at least 1/3 vaccine antigens (gag, pol, or env) throughout the immunizations. ELISpot responses were primarily mediated by CD8+ T cells. 9/11 subjects tested showed a positive CD8+CD107a+ Perforin+ Granzyme B+ response. HIV-1+ individuals, despite having well-controlled viral replication showed significantly different cytokine profiles compared to healthy controls. Importantly, baseline IL-12 p70, and MCP-1 levels were directly associated with response to the HIV-1 therapeutic vaccine.

      Conclusions: PENNVAX-B induced HIV-specific CTL responses in well-controlled HIV+ individuals. The pre-vaccination cytokine environment may provide the necessary signals for T cells to respond to therapeutic vaccination, suggesting that the cytokines examined could serve as potential adjuvants in a therapeutic vaccine strategy.

 
INO
6.01-0.25(-3.99%)Feb 5 4:00 PMEST